Synmosa Biopharma Corp (4114) AI Stock Analysis

Synmosa Biopharma Corp

(TPEx:4114)

Select Model

Rating:69Neutral

Price Target:TWD 30.00▲(8.11% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is supported primarily by strong profitability and balance-sheet quality, with valuation providing additional support. Weak cash conversion and bearish technical momentum materially limit the overall rating.

Positive Factors

Revenue Growth and ProfitabilityThe multi-year revenue uptrend and renewed growth in 2025 indicate continuing commercial traction across the business. Healthy net profitability provides resources to support research, regulatory activity, and commercialization while strengthening the company’s ability to fund operations over the next several quarters.

Negative Factors

Weak Cash ConversionThe sharp 2025 decline in free cash flow shows that accounting earnings are not consistently translating into cash available for reinvestment or shareholder returns. Persistent volatility could constrain funding flexibility and make future pharmaceutical investment more dependent on operating improvement.

Synmosa Biopharma Corp (4114) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 15.02B
Dividend Yield: 3.06%
Average Volume (3M): 839.84K
Price to Earnings (P/E): 17.7
Beta (1Y): 0.31
Revenue Growth: 11.40%
EPS Growth: 9.36%
Country: TW
Employees: 495
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Synmosa Biopharma Corp Business Overview & Revenue Model

Company Description

Synmosa Biopharma Corporation, established in Taipei, Taiwan, in 1980, operates as a dedicated specialty pharmaceutical enterprise. The company manages the entire lifecycle of pharmaceutical and healthcare products, from research and development to m...

Synmosa Biopharma Corp Financial Statement Overview

Summary

Strong profitability and a healthy, low-leverage balance sheet support the score, but substantially weaker operating and free cash flow reduce financial quality.

Income Statement

82Very Positive

Balance Sheet

86Very Positive

Cash Flow

58Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.68B	6.19B	5.55B	5.14B	4.39B	3.23B
Gross Profit	2.72B	2.54B	2.40B	2.12B	1.83B	1.29B
EBITDA	1.03B	1.12B	1.06B	1.01B	1.10B	507.92M
Net Income	775.69M	821.85M	684.68M	594.83M	799.09M	303.86M
Balance Sheet
Total Assets	15.28B	13.99B	12.30B	11.73B	11.20B	10.32B
Cash, Cash Equivalents and Short-Term Investments	2.78B	2.93B	1.89B	1.65B	1.42B	993.13M
Total Debt	3.36B	2.52B	2.55B	2.44B	3.37B	3.46B
Total Liabilities	5.41B	3.89B	3.91B	3.63B	4.55B	4.22B
Stockholders Equity	8.65B	8.76B	7.21B	6.71B	5.31B	4.71B
Cash Flow
Free Cash Flow	150.99M	130.44M	510.97M	242.16M	445.92M	312.74M
Operating Cash Flow	355.79M	411.57M	780.62M	511.93M	630.25M	454.86M
Investing Cash Flow	-1.14B	-663.53M	-336.80M	-717.87M	-69.33M	73.33M
Financing Cash Flow	345.94M	964.20M	-187.55M	37.24M	-347.94M	-297.57M

Synmosa Biopharma Corp Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4114 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6620	70Outperform	TWD 20.83B	66.76	―	1.52%	―	―
TW:4114	69Neutral	TWD 14.97B	17.66	―	3.06%	11.40%	9.36%
TW:1789	57Neutral	TWD 16.01B	904.98	―	1.45%	-4.75%	-90.91%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4147	47Neutral	TWD 16.47B	-103.67	―	―	7.02%	25.72%
TW:6547	40Underperform	TWD 16.94B	-409.93	―	―	44.37%	78.11%

* General Sector Average

Performance Comparison

TW:4114 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4114	Synmosa Biopharma Corp	27.75	-1.94	-6.53%
TW:1789	Scinopharm Taiwan, Ltd.	20.00	2.60	14.92%
TW:4147	TaiMed Biologics Inc.	61.90	-6.60	-9.64%
TW:6547	Medigen Vaccine Biologics Corp.	46.35	8.95	23.93%
TW:6589	EirGenix, Inc.	51.70	-30.20	-36.87%
TW:6620	Handa Pharmaceuticals Inc	136.50	17.95	15.14%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Synmosa Biopharma Corp AI Stock Analysis